Aberrant methylation of dynein axonemal heavy chain 17 (DNAH17) is associated with comprehensive clinic-pathological factors and can serve as a potential biomarker for tumor thrombosis in liver cancer patients (Fan et al., 2019). This evidence concerns the gene DNAH17 and liver cancer.